The Motley Fool
23 Sept 2026, 04:04 UTC · 2h ago
Verdict
Headline takes no side. We score VKTX +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 2 new · 1 priced in
Viking Therapeutics announced that participants using VK2735 lost 16% to 19% of their bodyweight after 21 weeks.
Newannounced on Tuesday
So whatSuccess in this trial increases the probability of FDA approval, which is the primary catalyst for valuation growth for a $3.5B mid-cap biotech.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Maintenance dosing of VK2735 allowed patients to maintain up to 97% of weight loss with every-other-week dosing and 90% with monthly dosing.
Newannounced on Tuesday
More positive than 92% of claims this week
Morgan Stanley estimates that annual sales of obesity drugs could reach $150 billion by 2035.
Priced ingeneral market projection
More positive than 63% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported highly encouraging clinical trial results for its obesity drug, leading to a significant stock price surge.
More negative than 68% of ticker scores this week
Identified as a current market leader that may face a formidable new challenger in Viking Therapeutics.
More negative than 68% of ticker scores this week
Identified as a current market leader that may face a formidable new challenger in Viking Therapeutics.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
5h ago
More positive than 56% of relationship scores this week
[mutual] Viking Therapeutics is described as a challenger to the obesity drug market dominated by Eli Lilly.
More positive than 56% of relationship scores this week
[mutual] Viking Therapeutics is described as a challenger to the obesity drug market dominated by Novo Nordisk.
—
VKTX hasn't traded since this ran. Last close $40.85 (Sep 22); the reaction starts at the next open.
VKTX chart →
